Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Public ClinicalTrials.gov record NCT02223052. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects
Study identification
- NCT ID
- NCT02223052
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Celgene
- Industry
- Enrollment
- 89 participants
Conditions and interventions
Conditions
- Acute Myeloid Leukemia
- Breast Cancer
- Genitourinary
- Glioblastoma Multiforme
- Hematological Neoplasms
- Hodgkin's Lymphoma
- Leukemia
- Lymphoma
- Melanoma
- Metastatic Breast Cancer
- Multiple Myeloma
- Myelodysplastic Syndromes
- Neoplasms
- Non-Hodgkin's Lymphoma
- Non-Small Cell Lung Cancer
- Osteosarcoma
- Renal Cell Carcinoma
- Sarcoma
- Small Cell Lung Cancer
- Thyroid Cancer
Interventions
- CC-486 Drug
- Vidaza Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 26, 2014
- Primary completion
- Jun 10, 2018
- Completion
- Dec 17, 2018
- Last update posted
- May 11, 2020
2014 – 2018
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Scottsdale Healthcare Research Institute | Scottsdale | Arizona | 85258 | — |
| Mayo Clinic - Arizona | Scottsdale | Arizona | 85259 | — |
| University of Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| Henry Ford Health System | Detroit | Michigan | 48202-268 | — |
| Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Greenville Hospital System | Greenville | South Carolina | 29605 | — |
| Vanderbilt- Ingram Cancer Center | Nashville | Tennessee | 37232-6307 | — |
| The Methodist Hospital Research Institute l | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02223052, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 11, 2020 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02223052 live on ClinicalTrials.gov.